Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report

JCO Precis Oncol. 2023 Mar:7:e2200508. doi: 10.1200/PO.22.00508.

Authors

François Poumeaud¹, Florence Dalenc^{1

2}, Quentin Mathevet³, Aurélie Brice³, Audrey Eche-Gass¹, Eleonora De Maio D'Esposito¹, Clémence Brac-de-la-Perriere¹, Fabienne Thomas^{1

2}

Affiliations

¹ Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
² Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université Toulouse III-Paul Sabatier, Toulouse, France.
³ Department of Pharmacology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

PMID: 36926988
DOI: 10.1200/PO.22.00508

No abstract available

Publication types

Case Reports

MeSH terms

Capecitabine / adverse effects
Dihydropyrimidine Dehydrogenase Deficiency* / diagnosis
Dihydropyrimidine Dehydrogenase Deficiency* / genetics
Fluorouracil / adverse effects
Genotype
Humans
Phenotype

Substances

Capecitabine
Fluorouracil